Stefan Palme1, Robert H Christenson2, Saeed A Jortani3, Richard E Ostlund4, Ruediger Kolm5, Guido Kopal6, Ruediger P Laubender7. 1. Roche Professional Diagnostics, Penzberg, Germany. Electronic address: Stefan.palme@roche.com. 2. School of Medicine, University of Maryland, Baltimore, MD, USA. Electronic address: rchristenson@umm.edu. 3. Department of Pathology and Laboratory Medicine, University of Louisville, Louisville, KY, USA. Electronic address: saeed.jortani@louisville.edu. 4. Division of Endocrinology, Metabolism and Lipid Research, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA. Electronic address: rostlund@wustl.edu. 5. Roche Professional Diagnostics, Penzberg, Germany. Electronic address: ruediger.kolm@roche.com. 6. Roche Professional Diagnostics, Penzberg, Germany. Electronic address: guido.kopal@roche.com. 7. Roche Professional Diagnostics, Penzberg, Germany; Institute of Medical Informatics, Biometry, and Epidemiology, Faculty of Medicine, University of Munich, Munich, Germany. Electronic address: ruediger.laubender@roche.com.
Abstract
OBJECTIVE: The multifunctional cytokine IL-13 is thought to play a central role in Type 2 inflammation in asthma. Serum periostin has been explored as a candidate biomarker for evaluating IL-13 activity in the airway. We describe the technical performance characteristics of a novel, fully automated immunoassay for the determination of periostin in serum. DESIGN AND METHODS: Limit of blank [LoB], limit of detection [LoD] and limit of quantitation [LoQ], linearity, precision and reproducibility across sites and lots were evaluated according to Clinical and Laboratory Standards Institute guidelines. Interferences and sample stability were also investigated. RESULTS: The pre-specified values for LoB (2ng/mL), LoD (4ng/mL) and LoQ (10ng/mL) were met. The assay was linear throughout the measuring range (10-160ng/mL) with recoveries within ±10% of target at concentrations >30ng/mL and within ±3ng/mL at concentrations ≤30ng/mL. Recovered periostin concentrations were also within ±10% of target in presence of 43 potentially interfering substances and drugs. Samples were stable across various storage conditions and durations (24h at room temperature, 7days at 4°C, 12weeks at -20°C, and 3 freeze/thaw cycles). Repeatability experiments resulted in CVs across samples and controls ranging from 0.9-1.5%. Intermediate precision was 1.2-1.7% and reproducibility including 3 testing sites and 3 reagent lots was 1.7-3.1%. The final assay correlates to the assay version used in previous clinical trials (Pearson's r=0.998, bias at 50ng/mL=1.2%). CONCLUSION: The performance evaluation of the Elecsys® Periostin immunoassay including a multicenter precision analysis demonstrated that the assay is suitable for measuring serum periostin at clinically important concentrations around 50ng/mL.
OBJECTIVE: The multifunctional cytokine IL-13 is thought to play a central role in Type 2 inflammation in asthma. Serum periostin has been explored as a candidate biomarker for evaluating IL-13 activity in the airway. We describe the technical performance characteristics of a novel, fully automated immunoassay for the determination of periostin in serum. DESIGN AND METHODS: Limit of blank [LoB], limit of detection [LoD] and limit of quantitation [LoQ], linearity, precision and reproducibility across sites and lots were evaluated according to Clinical and Laboratory Standards Institute guidelines. Interferences and sample stability were also investigated. RESULTS: The pre-specified values for LoB (2ng/mL), LoD (4ng/mL) and LoQ (10ng/mL) were met. The assay was linear throughout the measuring range (10-160ng/mL) with recoveries within ±10% of target at concentrations >30ng/mL and within ±3ng/mL at concentrations ≤30ng/mL. Recovered periostin concentrations were also within ±10% of target in presence of 43 potentially interfering substances and drugs. Samples were stable across various storage conditions and durations (24h at room temperature, 7days at 4°C, 12weeks at -20°C, and 3 freeze/thaw cycles). Repeatability experiments resulted in CVs across samples and controls ranging from 0.9-1.5%. Intermediate precision was 1.2-1.7% and reproducibility including 3 testing sites and 3 reagent lots was 1.7-3.1%. The final assay correlates to the assay version used in previous clinical trials (Pearson's r=0.998, bias at 50ng/mL=1.2%). CONCLUSION: The performance evaluation of the Elecsys® Periostin immunoassay including a multicenter precision analysis demonstrated that the assay is suitable for measuring serum periostin at clinically important concentrations around 50ng/mL.
Authors: Amisha V Barochia; Elizabeth M Gordon; Maryann Kaler; Rosemarie A Cuento; Patricia Theard; Debbie M Figueroa; Xianglan Yao; Nargues A Weir; Maureen L Sampson; Mario Stylianou; David F Choy; Cecile T J Holweg; Alan T Remaley; Stewart J Levine Journal: J Lipid Res Date: 2017-06-27 Impact factor: 5.922
Authors: Catherine E Hanratty; John G Matthews; Joseph R Arron; David F Choy; Ian D Pavord; P Bradding; Christopher E Brightling; Rekha Chaudhuri; Douglas C Cowan; Ratko Djukanovic; Nicola Gallagher; Stephen J Fowler; Tim C Hardman; Tim Harrison; Cécile T Holweg; Peter H Howarth; James Lordan; Adel H Mansur; Andrew Menzies-Gow; Sofia Mosesova; Robert M Niven; Douglas S Robinson; Dominick E Shaw; Samantha Walker; Ashley Woodcock; Liam G Heaney Journal: Trials Date: 2018-01-04 Impact factor: 2.279
Authors: O A Carpaij; F O W Muntinghe; M B Wagenaar; J W Habing; W Timens; H A M Kerstjens; M C Nawijn; L I Z Kunz; P S Hiemstra; G W Tew; C T J Holweg; C A Brandsma; M van den Berge Journal: Respir Res Date: 2018-06-07
Authors: Rennie L Rhee; Cecile T J Holweg; Kit Wong; David Cuthbertson; Simon Carette; Nader A Khalidi; Curry L Koening; Carol A Langford; Carol A McAlear; Paul A Monach; Larry W Moreland; Christian Pagnoux; Philip Seo; Ulrich Specks; Antoine G Sreih; Steven R Ytterberg; Peter A Merkel Journal: PLoS One Date: 2018-10-11 Impact factor: 3.240